On World Cancer Day, nothing is more “BELL” than advancing in cancer research
At IDIBELL, we have 27 cancer research groups, which address the disease from the most basic research to the clinical aspects: molecular mechanisms, and new therapies, epigenetics, population and prevention studies.
But what is cancer? Why do we say that it is a genetic disease? In cancer, changes in DNA cause cells to start dividing uncontrollably. Do you want to see it with your own eyes?
At IDIBELL, we know that research saves lives, that’s why we work every day to put our part in the research. We firmly believe that: AGAINST CANCER, RESEARCH.
On World Cancer Day, the words prevention, research and treatment are more “BELL(s)” than ever
Prevention: Knowing what the cancer cause is essential to act in time. Nothing is more effective against cancer than doing everything in our power to prevent it.
We know that diets that promote inflammation can increase the risk of breast cancer by up to 12%:
Our tobacco control research group has been awarded by the WHO:
Research to find new treatments, but also for early diagnosis that allows us to act in time.
Álvaro Carmona from the infection and cancer research group tells us about how we can detect cervical cancer without going to the hospital:
Bárbara Rivera from the hereditary cancer group presented in the previous sLHam rare cancer predisposition syndromes:
In the treatment, we are also together with patients to know their needs and improve the quality of life during therapy.
In the last Research and Health Day researchers, clinicians and patients shared a good time:
On World Cancer Day, dedicating your life to the research of a new treatment is very “BELL”
One of the strategies against cancer is to give our bodies tools to fight cancer. How can we do it? Helping the immune system. Lidia Franco tells us about it in this video from Stand Up Science:
A study with IDIBELL participation has shown that breast cancer cells create collagen shields to protect themselves from the immune system. Preventing the creation of these shields reduces tumor growth:
A drug that modulates the immune system to recognize and attack tumors increases the life expectancy of highly aggressive intraocular cancer. This is the conclusion of a clinical trial that has brought this drug to clinical practice:
We have also participated in two other trials that have shown that CART cell immunotherapy increases survival in patients with aggressive B-cell lymphoma who do not respond to chemotherapy: